Zobrazeno 1 - 10
of 19
pro vyhledávání: '"W E, Fitzsimmons"'
Publikováno v:
The Journal of Immunology. 153:1836-1846
FK506 was evaluated as the sole graft-vs-host disease (GVHD) preventive agent in murine recipients of fully allogeneic donor grafts. FK506 (36 mg/kg given as a suspension on days 0 through 13, then three times per wk through day 29 post-bone marrow t
Autor:
N, Ahsan, C, Johnson, T, Gonwa, P, Halloran, M, Stegall, M, Hardy, R, Metzger, C, Shield, L, Rocher, J, Scandling, J, Sorensen, L, Mulloy, J, Light, C, Corwin, G, Danovitch, M, Wachs, P, VanVeldhuisen, K, Salm, D, Tolzman, W E, Fitzsimmons
Publikováno v:
Transplantation. 72(2)
A previous report described the 1-year results of a prospective, randomized trial designed to investigate the optimal combination of immunosuppressants in kidney transplantation. Recipients of first cadaveric kidney allografts were treated with tacro
Autor:
G D, MacFarlane, R, Venkataramanan, S V, McDiarmid, J D, Pirsch, D G, Scheller, D L, Ersfeld, W E, Fitzsimmons
Publikováno v:
Pediatric transplantation. 5(2)
The clinical utility of tacrolimus monitoring in adults has been well documented. The present study compared tacrolimus monitoring in a pediatric population of 34 liver transplant patients in four US centers with an adult population of 111 patients i
Autor:
C, Johnson, N, Ahsan, T, Gonwa, P, Halloran, M, Stegall, M, Hardy, R, Metzger, C, Shield, L, Rocher, J, Scandling, J, Sorensen, L, Mulloy, J, Light, C, Corwin, G, Danovitch, M, Wachs, P, van Veldhuisen, K, Salm, D, Tolzman, W E, Fitzsimmons
Publikováno v:
Transplantation. 69(5)
Our clinical trial was designed to investigate the optimal combination of immunosuppressants for renal transplantation.A randomized three-arm, parallel group, open label, prospective study was performed at 15 North American centers to compare three i
Autor:
H, Chen, J, Peng, H, Luo, M, Loubeau, X, Wan, D, Xu, S, Qi, M D, Vu, P, Daloze, W E, Fitzsimmons, I, Bekersky, J, Peets, S N, Sehgal, J, Wu
Publikováno v:
Transplantation. 69(8)
In nonprimates, organ allografts are often not rejected after withdrawal of immunosuppression. In this study, we examined whether such a phenomenon also occurs in primates.Vervet monkeys were transplanted with renal allografts and treated for 60 days
Autor:
S, Qi, D, Xu, J, Peng, M D, Vu, J, Wu, I, Bekersky, W E, Fitzsimmons, J, Peets, S, Sehgal, P, Daloze, H, Chen
Publikováno v:
Transplantation. 69(7)
Our previous studies confirmed that tacrolimus (FK506) and sirolimus [rapamycin (RAPA)], in combination, are not antagonistic but are synergistic in the prolongation of heart and small bowel grafts in the rodent. The aim of this study was to confirm
Autor:
M D, Vu, S, Qi, D, Xu, J, Wu, W E, Fitzsimmons, S N, Sehgal, L, Dumont, S, Busque, P, Daloze, H, Chen
Publikováno v:
Transplantation. 64(12)
Combined use of tacrolimus (FK506) with sirolimus (rapamycin [RAPA]) was examined in a model of vascularized heart allograft in the rat. For prevention of acute rejection, three different combinations of low doses of FK506 and RAPA from day 1 up to d
Autor:
S M, Devine, R B, Geller, L B, Lin, S P, Dix, H K, Holland, D, Maurer, K, O'Toole, J, Keller, D G, Connaghan, L T, Heffner, C D, Hillyer, G E, Rodey, E F, Winton, R M, Maher, W E, Fitzsimmons, J R, Wingard
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 3(1)
Initial studies of FK506 combined with methotrexate (MTX) in patients receiving unrelated donor BMT have demonstrated a possible-decrease in the incidence of severe GVHD but high rates of severe stomatitis and nephrotoxicity. With this background, we
Autor:
R A, Nash, L A, Piñeiro, R, Storb, H J, Deeg, W E, Fitzsimmons, T, Furlong, J A, Hansen, T, Gooley, R M, Maher, P, Martin, P A, McSweeney, K M, Sullivan, C, Anasetti, J W, Fay
Publikováno v:
Blood. 88(9)
The safety and potential efficacy of FK506 in combination with a short course of methotrexate (MTX) for the prevention of acute graft-versus-host disease (GVHD) after marrow transplantation from HLA-matched unrelated donors was evaluated in a single-
Autor:
J W, Fay, J R, Wingard, J H, Antin, R H, Collins, L A, Piñeiro, B R, Blazar, R, Saral, B E, Bierer, D, Przepiorka, W E, Fitzsimmons, R M, Maher, D J, Weisdorf
Publikováno v:
Blood. 87(8)
FK506 (Tacrolimus) is an immunosuppressive drug that blocks the activation of antigen-specific T lymphocytes, a major component in the pathogenesis of graft-versus-host disease (GVHD). This study was designed to obtain first estimates of the safety a